Journal article
Safety and Patient-Reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-
Lyria Amari, Pascale Tomasini, Emmanuelle Dantony, Gaëlle Rousseau-Bussac, Charles Ricordel, Laurence Bigay Game...